Pure Biologics is a Wrocław-based biotech startup focused on early-stage development of drug candidates, diagnostic tools and medical devices. The company uses its PureSelect platform to select new antibodies and is developing an immuno-oncological drug (PureBIKE) targeting triple-negative breast cancer (TNBC). PureBIKE aims to produce an antibody fragment that activates natural killer immune cells to inhibit tumour growth and metastases. TNBC is a heterogeneous, aggressive form of breast cancer that accounts for roughly 12–17% of cases and currently lacks targeted therapies, leaving chemotherapy as the main option. Pure Biologics says PureBIKE is the third drug project in its pipeline and plans to start one or two more projects in the coming quarters. Financially, the company announced a €6.7 million funding award for PureBIKE and had previously raised €2.3 million from investors earlier this year.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2019